Blackstone

Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders

The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.

Takeda agrees $2.3bn sale of Japanese consumer health unit

Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs. The drugmaker is divesting Takeda Consumer Healthcare, which operates mainly in Japan, to private equity group Blackstone for 242 billion yen ($2.3 billion), with the deal expected to close in March of next year. …

Takeda agrees $2.3bn sale of Japanese consumer health unit Read More »

Takeda to Divest its Consumer Health Unit to Blackstone for $2.3B in Japan

Shots: Takeda and Blackstone sign an agreement to divest it consumer health care business unit for $2.3B. The transaction expected to be closed by Mar 31, 2021 The portfolio to be divested includes OTC medicines and health products along with its lead product in the region, Alinamin. Blackstone plans to develop the business together with …

Takeda to Divest its Consumer Health Unit to Blackstone for $2.3B in Japan Read More »

Blackstone’s $4.7B acquisition of Ancestry raises privacy questions

Ancestry, which grew from a genealogy tracking tool to offering DNA tests for a number of healthconditions, reached a deal to be acquired by Blackstone for $4.7 billion. But privacy advocates have raised concerns over the deal — namely, what would happen to users’ health data?